1. Home
  2. HCKT vs LYEL Comparison

HCKT vs LYEL Comparison

Compare HCKT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hackett Group Inc (The).

HCKT

Hackett Group Inc (The).

HOLD

Current Price

$11.13

Market Cap

285.1M

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$14.51

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCKT
LYEL
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.1M
320.1M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
HCKT
LYEL
Price
$11.13
$14.51
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$17.00
$30.60
AVG Volume (30 Days)
244.8K
135.6K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
3.67%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$285,862,000.00
$36,000.00
Revenue This Year
$2.55
N/A
Revenue Next Year
$5.07
$8,712.13
P/E Ratio
$32.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.16
$11.47
52 Week High
$21.33
$45.00

Technical Indicators

Market Signals
Indicator
HCKT
LYEL
Relative Strength Index (RSI) 55.53 55.43
Support Level $9.90 $11.87
Resistance Level $11.64 $15.63
Average True Range (ATR) 0.34 0.93
MACD 0.00 -0.02
Stochastic Oscillator 77.17 46.54

Price Performance

Historical Comparison
HCKT
LYEL

About HCKT Hackett Group Inc (The).

The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: